Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 5/20 | 0.67 |
| ▸ | CYP1A1 | P04798 | 3/20 | 0.67 |
| ▸ | HPGD | P15428 | 3/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.67 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.67 |
| ▸ | PDE4A | P27815 | 2/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | KCNA3 | P22001 | 7/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3612950 | 0.82 | KCNA3 (0.53) | CYP3A4CYP1A1HPGDMAPK1CYP1A2 | |
| SCHEMBL10300861 | 0.81 | CYP3A4 (0.72) | CYP3A4CYP1A1HPGDMAPK1CYP1A2 | |
| Khellin SCHEMBL9655 | 0.81 | CYP3A4 (1.00) | CYP3A4CYP1A1HPGDMAPK1CYP1A2 | |
| Khellin SCHEMBL30839911 | 0.81 | CYP3A4 (1.00) | CYP3A4CYP1A1HPGDMAPK1CYP1A2 | |
| SCHEMBL3609628 | 0.80 | CYP3A4 (0.82) | CYP3A4CYP1A1HPGDMAPK1CYP1A2 | |
| SCHEMBL3608653 | 0.78 | KCNA3 (0.47) | CYP3A4CYP1A1HPGDMAPK1CYP1A2 | |
| SCHEMBL1343992 | 0.77 | CYP3A4 (0.78) | CYP3A4CYP1A1HPGDMAPK1CYP1A2 | |
| SCHEMBL13920849 | 0.74 | CYP3A4 (0.81) | CYP3A4CYP1A1HPGDMAPK1CYP1A2 | |
| SCHEMBL12133429 | 0.73 | CYP3A4 (0.77) | CYP3A4CYP1A1HPGDMAPK1CYP1A2 | |
| SCHEMBL13920848 | 0.72 | CYP3A4 (0.81) | CYP3A4CYP1A1HPGDMAPK1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309545-B2 | Benzofuran potassium channel blockers and uses thereof | BIONOMICS LIMITED (AU) | 2012-11-13 | — | — | US | disclosed |
| US-8217189-B2 | Chromenone potassium channel blockers and uses thereof | BIONOMICS LIMITED (AU) | 2012-07-10 | — | — | US | disclosed |
| US-20100087430-A1 | NOVEL BENZOFURAN POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2010-04-08 | — | — | US | disclosed |
| US-20090298931-A1 | NOVEL CHROMENONE POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2009-12-03 | — | — | US | disclosed |
| WO-2008040057-A1 | NOVEL BENZOFURAN POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2008-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087430-A1 | NOVEL BENZOFURAN POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | KCNA3, KCNB1, KCNK3 | CYP3A4 2204/4885CYP1A1 2562/4885HPGD 3397/4885 |
| US-20090298931-A1 | NOVEL CHROMENONE POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | KCNK3, KCNA3, KCND3 | CYP3A4 2101/4885CYP1A1 2690/4885HPGD 3387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.